Board of Directors

Allan C. Silber is the Chairman of Point Biopharma. He is also chairman of Verity Pharmaceuticals, a specialty pharmaceutical company and also chairs Heritage Global Inc., a global financial services and asset trading company providing corporate and financial asset monetization, advisory, and valuation services. Mr. Silber has an extensive background in the private equity, real-estate and financial services fields. Mr. Silber is the former CEO of Street Capital Group Inc. and Counsel Corporation

Dr. Raj Malik, M.D. is the Chief Medical Officer of G1 Therapeutics. Previously, he served as Chief Medical Officer and management board member at Agennix AG, where he was responsible for research and development. Prior to Agennix AG, he served as Chief Medical Officer at Adherex Technologies, where he directed the company’s global regulatory strategy and clinical development programs. Dr. Malik also served in oncology clinical development positions at EMD Pharmaceuticals and Bristol-Myers Squibb. Dr. Malik currently serves on the board of directors of Meryx, Inc.

Dr. Malik received his M.D. from the University of Sheffield Medical School in the UK. He completed his residency at Duke University Medical Center and fellowships at the Children’s Hospital of Philadelphia and Duke University Medical Center. During his academic career, he was an assistant professor at the University of Virginia, where he conducted basic science and clinical research in addition to patient care and teaching.

David Lubner is a senior finance executive with more than 25 years of experience in the life sciences industry. Mr. Lubner most recently served as Executive Vice President and Chief Financial Officer of Ra Pharma, which was acquired by UCB in April 2020. Before joining Ra Pharma, he served as Chief Financial Officer of Tetraphase Pharmaceuticals, Inc. a biotechnology company, from its inception in 2006 to 2016, as Chief Financial Officer of and PharMetrics Inc., a leading patient-based pharmacy and medical claims data informatics company from 1999 until it was acquired by IMS Health in 2005 and as Vice President and Chief Financial Officer of and at ProScript, where Velcade® (bortezomib), a therapy widely used for the treatment of multiple myeloma, was discovered.

Mr. Lubner currently serves on the Board of Directors of Dyne Therapeutics (Nasdaq: DYN), a company developing life-transforming therapies for patients with serious muscle diseases, Gemini Therapeutics, Inc.,(Nasdaq: GMTX) a clinical-stage precision medicine company developing novel therapeutic compounds to treat genetically defined, age-related macular degeneration, Vor Biopharma, Inc. (Nasdaq: VOR) a cell therapy company combining a novel patient engineering approach with targeted therapies to treat patients suffering from hematological malignancies, and several other private companies He previously served on the Board of Directors of Nightstar Therapeutics plc (Nasdaq: NITE), a company focused on the development of one-time retinal gene therapies for patients suffering from rare inherited retinal diseases, which was acquired by Biogen in June 2019. Mr. Lubner is a Certified Public Accountant. He received his B.S. in business administration from Northeastern University and an M.S. in taxation from Bentley University.

Dr. Neil Fleshner graduated with a medical degree from the University of Toronto in 1988. He completed specialty training in urologic surgery and oncology from 1993 to 1996, received a Master’s in Public Health in epidemiology from Columbia University in 1997, and completed his oncology training at Memorial Sloan-Kettering Cancer Center.

Dr. Fleshner is certified in both urology and epidemiology. Dr. Fleshner is also a Professor of Surgery at the University of Toronto. In the past, he has served as the Head of the Division of Urology at the University Health Network, and the Head of Genitourinary Cancer Site group at the Princess Margaret Hospital. He also holds the prestigious Love Chair in prostate cancer prevention at Princess Margaret Hospital.

Dr. Joe McCann, Ph.D. has served as POINT’s Chief Executive Officer since January 2020 and as a member of its board of directors since September 2019. Dr. McCann has overall responsibility for the day-to-day operations of POINT. Prior to this role, Dr. McCann was most recently the Chief Executive Officer and President of the Centre for Probe Development and Commercialization, where he led the formation and growth of the company’s contract development and manufacturing operations and the build out of multiple radiopharmaceutical manufacturing facilities. Prior to joining CPDC in 2010, Dr. McCann was a scientist in Pharmaceutical Development at GlaxoSmithKline from July 2006 until May 2010, with responsibility for developing products across all stages of clinical development. Dr. McCann has a Ph.D. in biochemistry from McMaster University.